Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Goodall

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Clinical and Experimental Immunology|April 16, 2008
Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudyC T Burton, R L Goodall, A Samri, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2011
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoringD T Dunn, R L Goodall, P Munderi, et al.
HIV Medicine|May 24, 2011
Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)E R Feeney, C Chazallon, N O'Brien, et al.
BMC Medicine|November 4, 2020
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trialP P J Phillips, A Van Deun, S Ahmed, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 28, 2022
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TBD M Kokebu, S Ahmed, R Moodliar, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2014
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in UgandaR L Goodall, D T Dunn, T Pattery, et al.
HIV Medicine|May 3, 2021
Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UKH Asad, I J Collins, R L Goodall, et al.
Lancet (London, England)|July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial, P Yeni, D A Cooper, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Clinical and Experimental Immunology|April 16, 2008
Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudyC T Burton, R L Goodall, A Samri, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2011
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoringD T Dunn, R L Goodall, P Munderi, et al.
HIV Medicine|May 24, 2011
Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)E R Feeney, C Chazallon, N O'Brien, et al.
BMC Medicine|November 4, 2020
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trialP P J Phillips, A Van Deun, S Ahmed, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 28, 2022
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TBD M Kokebu, S Ahmed, R Moodliar, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2014
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in UgandaR L Goodall, D T Dunn, T Pattery, et al.
HIV Medicine|May 3, 2021
Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UKH Asad, I J Collins, R L Goodall, et al.
Lancet (London, England)|July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial, P Yeni, D A Cooper, et al.
Pageof 2